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Understanding the biology of cancer at the cellular and molecular levels, and the 
application of such knowledge to the patient, has opened new opportunities and 
uncovered new obstacles to quality cancer care delivery. Benefits include our ability 
to now understand that many, if not most, cancers are not one-size-fits-all. Cancers 
are a variety of diseases for which intervention may be very different. This approach is 
beginning to bear fruit in gynecologic cancers where we are investigating therapeutic 
optimization at a more focused level, that while not yet precision care, is perhaps much 
improved. Obstacles to quality care for patients come from many directions. These 
include incomplete understanding of the role of the mutant proteins in the cancers, the 
narrow spectrum of agents, broader mutational profiles in solid tumors, and sometimes 
overzealous application of the findings of genetic testing. This has been further com-
promised by the unbridled use of social media by all stakeholders in cancer care often 
without scientific qualification, where anecdote sometimes masquerades as a fact. The 
only current remedy is to wave the flag of caution, encourage all patients who undergo 
genetic testing, either germline or somatic, to do so with the oversight of genetic coun-
selors and physician scientists knowledgeable in the pathways involved. This aspiration 
is accomplished with  well-designed clinical trials that inform next steps in this complex 
and ever evolving process.
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inTRODUCTiOn
Cancer care delivery was once relatively simple due to the few available drugs, limited understanding 
of the complexity of the cancers, and less sophisticated diagnostic and therapeutic interventions. 
The exponential increase in knowledge brought about by microdissection of the genome, kinome, 
and other – omes, has yielded new classifications of cancers, classes of agents, different methods for 
dose determination, and increasing potential for personalization. This rapidly expanding knowledge 
creates the potential for diversity and inequality in cancer care.
Understanding the roles and limitations of these new resources narrows that treatment delivery 
gap. The harmonization of diagnostic approaches and expectations for each patient with a defined 
cancer histology and/or genomic subtype will assure the same care for all. Monitoring for treat-
ment decisions should be consistent and driven by objective data, change in responsiveness, and/or 
toxicity parameters. Recognition of when the risk/benefit balance has shifted toward harm remains 
a critical element.
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Optimization of cancer treatment in the molecular era 
is not always defined by the molecular make up of cancer. 
Characterization of the molecular biomarker utility across a 
type of cancer and then from the patient perspective needs to 
be coordinated. The charge to the molecular oncologist is to 
recognize when compelling data from high-level evidence 
identifies a molecular finding of therapeutic importance. In most 
cancers, this remains a goal. We have few validated biomarkers 
to guide us in women’s cancers and an abundance of molecular 
noise to dampen. Molecular testing is often done for reasons that 
the patients do not understand, and the testing costs thousands 
of dollars, frequently yielding little guidance. Determining and 
validating selective targets, target-drug pairing, and best patient 
practices will take carefully designed studies with well consid-
ered correlative science, requiring patients, time, and support. 
Currently, other than the use of germline BRCA1/2 mutation 
testing and Lynch Syndrome testing, application of molecular 
diagnostics to the broad gynecologic cancer population is 
premature.
BiOMARKeRS: wHAT, wHen, AnD wHY
Biomarkers, Definition?
A biomarker generally refers to a measured characteristic, which 
may be used as an indicator of some biological state or condi-
tion. Biomarkers may be developed to address multiple purposes 
related to patient diagnosis and selection, or drug and treatment 
effect. Molecular diagnostics can be translocations, such as BCR-
ABL for chronic myelogenous leukemia, expression of mutant 
proteins or inappropriate protein expression, such as p53 in 
many solid tumors, or loss of expression as with E-cadherin loss 
in lobular breast cancer.
Molecular biomarkers can be used for therapeutic selection. 
Amplification of HER2 is both a diagnostic and selective bio-
marker. It helps classify a type of breast cancer, and its presence 
determines targeted therapy selection. Identification of specific 
mutations in lung cancer, such as EGFR mutations, drives selec-
tion of the therapeutic classes of targeted agents. Alternatively, 
broad sequencing in a discovery mode can be used to determine 
targetable molecular events on a case-by-case basis. This is the 
hypothesis underlying the NCI MATCH study (NCT02465060) 
and other basket studies.
Biomarkers also may be used as surrogates of clinical behavior, 
such as those readily measured in blood-like, CA-125 and PSA. 
These biomarkers may also be evaluated for prognostic and/
or predictive potential. Prognostic biomarkers are those that 
dichotomize clinical outcomes, such as survival, in a therapy-
agnostic fashion (Figure 1A). They are most often defined based 
upon correlative findings. Clinical biomarkers used commonly as 
prognostic directors in women’s cancers include stage, grade, age, 
lymphovascular space invasion, and number of positive lymph 
nodes (1).
Predictive biomarkers are most elusive and potentially 
most valuable (2, 3). They dichotomize outcomes in a therapy-
specific fashion (Figure 1B). HER2, a diagnostic and selection 
biomarker, is both prognostic and predictive, shifting the full 
cohort outcome and biomarker positive patients in the upper set 
of curves (Figure  1C) (4, 5). HER-2AMP breast cancer patients 
had a worse prognosis when given the same treatment as their 
HER-2 non-amplified counterparts. The introduction of HER-2 
targeted therapy has changed that poor prognosis. Now, HER-
2AMP is a biomarker predictive of responsiveness to HER-2 
targeted agents.
integral vs. integrated Trial Biomarkers
Rigorous biomarker development is important. It requires 
qualification, optimization, and validation at levels of pre-
analytic and analytical methods. Standard operating procedures 
for the collection and processing of patient-derived materials, 
pre-analytic methodologies, assure the collection of high-quality 
specimens. What samples, how they are taken, how and when 
they are processed, and the what/how/when of storage are critical 
pre-analytical variables (6). Quality control of reliability, repro-
ducibility, variance, and cut-off determination are key analytical 
variables (7, 8).
Biomarkers that are required for the execution of a trial and/
or the application of an agent are integral to the therapeutic direc-
tion. Integral biomarkers require the tightest pre-analytical and 
analytical standards, and if involved in patient care, must be done 
in appropriately certified laboratories. Integrated biomarkers are 
those that are included in clinical trials in hypothesis-directed 
objectives to be executed in a controlled, optimized fashion, 
to validate them for future integral application. Integral and 
integrated biomarkers use assay methodologies that are well past 
exploration and discovery and are moving toward anticipated use 
or standard of care. Understanding where a molecular biomarker 
is in development is critical to its proper application to the patient 
treatment setting.
Fit-for-Purpose Biomarkers
The complexity of biomarker selection underscores the impor-
tance of using biomarkers that are fit-for-purpose (FFP). A FFP 
biomarker is defined by its intended use and by the biomarker 
assay method performance (2). The intended use or purpose 
of the biomarker or biomarker assay data is described in many 
ways, including pharmacokinetic, pharmacodynamic, diagnos-
tic, exploratory, safety, enrollment, or companion diagnostic. 
A FFP biomarker is categorized as (a) integral, used for patient 
or treatment selection, (b) integrated, used to established treat-
ment or disease state effects, or (c) exploratory, used descrip-
tively or for screening for effects that are unestablished or 
poorly described. The stringency of the proposed assay method 
validation is defined and determined by the biomarker category, 
risk–benefit to the patient, and invasiveness. Biomarker assay 
method performance must be reliable and reproducible, and 
the assay must have well-defined performance characteristics. 
Performance metrics are qualitative and quantitative and include 
measures of sensitivity, specificity, accuracy, precision/robust-
ness, stability, reference intervals/standards and cut-points 
(dynamic range), calibrators, range of quantification, dilutional 
linearity, sample re-analysis, interference, and normal signal 
FiGURe 1 | Predictive vs. prognostic biomarkers. Prognostic biomarkers (A) have similar change in outcome with therapy that is independent of the biomarker 
status. Predictive biomarkers (B) have a treatment/outcome interaction, seen in this example as improvement with treatment in biomarker+ cases (vertical arrow), 
with absence of change in the biomarker− cases (horizontal arrow). Biomarkers that may be both prognostic and predictive  (C) will shift the biomarker+ curve the 
same or greater if both the prognostic and predictive effects are positive. If one is positive and the other is negative, the outcome may cancel. This is a more 
complex situation to dissect.
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distribution. Methodology performance evaluation is itera-
tive and is updated throughout the life cycle of the biomarker 
development (9).
The circumstances under which biomarker testing is applied 
should be considered in the context of standard testing issues 
when planning a clinical trial. Each trial should have a biomarker 
prioritization plan. Parallel development of drugs and biomarkers 
is the key to rapid and purposeful progress. Many prognostic, but 
few predictive, biomarkers are under development. Such develop-
ment is found in the translational literature and in clinical trial 
design where such questions are included.
OPTiMiZinG MOLeCULAR CAnCeR CARe 
DeLiveRY FOR THe PATienT
when is it Precision Treatment or 
Scientific experiment?
Optimal use of diagnostic and therapeutic resources requires 
understanding when there is potential for reliable data or when 
it is a shot in the dark. Few biomarkers have been validated in 
gynecologic cancers. They include the serum biomarkers for germ 
cell tumors (βHCG and αFP) (10), recurrent epithelial ovarian 
cancer (CA-125 and HE4) (11–14), endometrial cancer (HE4) (15), 
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granulosa cell tumors (inhibin) (16), and the molecular markers of 
germline or somatic BRCA1 or BRCA2 mutation (1, 17–19).
Driver molecular events have been identified and validated 
in some sarcomas and solid tumors. Drivers are molecular 
events that, based upon preclinical modeling and clinical testing, 
initiate, promote, and/or maintain malignancy in an obligatory 
fashion. Specific inhibition of driver(s) in patients results in 
dramatic clinical response. For example, the bcr-abl translocation 
results in constitutive activation of abl kinase and drives chronic 
myelogenous leukemia. Its inhibition with imatinib, dasatinib, 
and others is the gold standard example to define driver function 
(20). As impressive as these events are in preclinical models and 
in patients, to date, the only curative driver events have been 
identified in leukemias.
The most common drivers identified cause gain-of-function 
oncogenic behaviors, commonly by translocation, mutation, 
or occasionally by amplification. The regions in oncogenes that 
result in unfettered activation are few and are “hot spot” muta-
tions for which focused screening can be done, or are identifiable 
breakpoints at translocations causing an activation event that 
can be readily identified. Similarly, oncogenic mutations, such as 
those seen in c-kit and PDGFR in gastrointestinal stromal tumors 
(21, 22) and translocations, such as the driving ALK translocation 
in non-small cell lung cancers (23), likewise, cause constitutive 
kinase or receptor activity. Inhibition of oncogenic signaling 
pathways by small molecule inhibitors results in impressive 
objective clinical effects (24, 25).
Inhibition of tumor suppressor genes is another mechanism 
through which carcinogenic behaviors are unmasked. Loss-of-
function of tumor suppressor genes occurs with one of several 
events, such as mutational introduction of a stop codon that 
prevents transcription and translation of an active protein or 
by mutation that inactivates or alters function of the translated 
protein. These events are seen in p53 in ovarian and endometrial 
cancers. Unlike the hotspot mutational foci seen in oncogenic 
gain-of-function mutations or translocations, tumor suppressor 
gene mutations and rearrangements can and do occur all along 
the gene with “hot spots” that may identify population founder 
events. The more common gain-of-function p53 mutation is one 
where the mutation abrogates normal p53 checkpoint activity 
allowing cells to move through the cell cycle without stopping 
to repair the DNA damage. Protein is not lost and is seen as 
strong and broad staining of p53 by immunohistochemistry. The 
loss-of-function events, where p53 protein is lost, also have been 
identified in gynecologic cancers (26), and the early data suggest 
that there may be biological differences caused by the two muta-
tional events (27). Yet, there are no validated specific or selective 
therapeutic opportunities related to p53 mutations. Thus, while 
serving a diagnostic and prognostic purpose, p53 has no targeted 
therapeutic direction or predictive value.
BRCA1 and BRCA2 are tumor suppressor genes. Homozygous 
genomic injury with resultant loss of both functional alleles has 
strong biologic effect in reduction of homologous recombination 
double-stranded DNA repair (28). Germline monoallelic loss 
predisposes to breast and ovarian cancers yielding a very high 
lifetime risk and has been used to trigger cancer prevention 
approaches. Recently, PARP inhibitors, a drug class within the 
broad category of DNA repair inhibitors, have been shown to be 
more active in women with germline loss (29). BRCA mutations 
have thus been validated as predictive biomarkers in this setting. 
BRCA mutation testing has been approved by the US FDA as a 
companion diagnostic for selection for treatment with olaparib; 
it is a predictive and selective biomarker approved as related 
specifically to treatment with the PARP inhibitor, olaparib, for 
women in fourth or later ovarian cancer recurrence. Despite 
inclusion in the EMA approval of olaparib, the role of somatic 
BRCA mutation remains unclear and has not been accepted by 
the US FDA. Clarification of homozygous mutation vs. single 
somatic mutation and issues of gene dosage should be addressed.
when is Molecular Testing Reasonable for 
Standard of Care Oncologic intervention?
A strong family history alone does not predict accurately the full 
spectrum of women with BRCA mutation-associated ovarian 
cancer. Thus, NCCN and SGO recommend testing all women with 
high-grade serous ovarian cancer. This can have implications for 
the patient’s family if she is found to harbor a deleterious germline 
mutation, found in approximately 17% of the newly diagnosed 
high-grade serous ovarian cancer patients (30). Lack of mutation 
has not been shown to be of biologic value. Knowledge of BRCA 
status may have impact upon cancer care for investigational uses, 
as defined by clinical trial entry criteria, but in the US does not 
affect treatment opportunities until fourth treatment line. The 
effect on the patient and her family is also of importance and is 
addressed elsewhere in this Research Topic.
Risk panel testing, whole exome and genome testing, and 
testing of oncogene panels are done as “standard of care” in some 
centers and often requested in order to find something actionable. 
Panel testing is the examination of a series of potentially impor-
tant risk genes, such as the BROCA panel defined by Swisher 
and colleagues (31, 32). It includes the Lynch Syndrome genes 
and other genes with low frequency, but deleterious germline 
mutations, including PALB2, RAD51c, and RAD51d. Mutations 
in these genes may be linked to the risk of ovarian and other 
cancers, a prognostic event, but there is no validated predictive 
function (31). There are no data that exome or whole genome 
sequencing is medically useful or cost-effective for gynecologic 
cancer patients. Too often, this testing is presented to or by the 
patient as an expectation, related to receipt of care. The facts 
and foibles are not presented in depth, and often no or minimal 
informed consent is done, since many of these are commercially 
available. This includes not fully informing the patient about the 
financial implication and the support or lack thereof by their 
insurance coverage. The number of truly actionable events, where 
there are validated clinical outcomes linked to genomic findings, 
are exceptionally rare in gynecologic cancers and do not inform 
patient care. Such testing should be done in the context of a clini-
cal trial, such as the NCI MATCH (NCT02465060).
Opportunities and Obstacles
Molecular characterization of gynecologic and other cancers 
created a great opportunity for learning about the behavior of 
the cancer, its heterogeneity, how subclones outgrow during 
TABLe 1 | Obstacles and opportunities of molecular testing 
in gynecologic cancers.
Opportunities Obstacles
Advance understanding of cancer(s) Intrinsic cancer elements
• Identify novel drivers and 
facilitators
• Unclear functional status of mutation
• Examine heterogeneity • Heterogeneity
• Dissect cause of molecular events • Tumor–microenvironment interactions
• Molecular divergence
• Activation of secondary pathways
Knowledge on a per-patient basis for 
therapeutic selection
Selection approaches may miss optimal 
personal opportunities
Translate science to therapeutic 
opportunities
Mechanisms of resistance and risk of 
negating effects of subsequent targeted 
agents
Drive novel trial designs and 
statistical models
Cost: patient time (from work, travel, 
etc), assay costs, and physician and 
counseling costs
Low clinical trial participation
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treatment, and to identify therapeutic opportunities (Table  1). 
These prospects may have little benefit to the individual patient 
but in aggregate may provide key information that, when mined, 
can yield important new insights. This was demonstrated by the 
remarkable progress occurring after broader characterization of 
BRCA mutation carriers. Those advances resulted in identifica-
tion of the precursor fallopian tube lesion for ovarian cancer, 
an understanding of the importance of different mechanisms of 
DNA repair, and the advancement of several new classes of DNA 
repair inhibitory agents.
The further understanding of molecular aspects of cancer has 
resulted in novel trial designs and statistical models. Trial designs, 
categorizing therapy based upon common molecular events, 
such as NCI MATCH (NCT02465060), are examining tissue for 
molecular events. It then seeks to match the molecular event to a 
drug that may target the molecular event. This study recognizes that 
the role of the molecular event in a given cancer is unknown. This 
is a direction to refer women with more rare ovarian cancers for 
which trials are not available and phase 1 options may be limited.
Several studies have been published with similar target-
matching approaches. The SHIVA investigators found that the 
use of molecularly targeted agents outside their indications does 
not improve outcome over physician’s choice, underscoring the 
requirement for understanding the biology and selection oppor-
tunities within cancer/drug pairing (33). Schwaederle and col-
leagues (34) showed clinical benefits in the arm in which patients 
were matched to therapeutics by molecular targets over the arm 
with standard of care treatment. However, it did not present the 
cancer breakdown of the participating patients, preventing read-
ers from determining if the positive results may have been driven 
by an overabundance of cancers with proven targets, such as non-
small cell lung cancer subsets. Another study evaluated the role of 
the use of selection biomarkers in clinical trials of FDA-approved 
agents (35). This study showed improvement with the application 
of selection biomarkers where there was a validated biomarker for 
the targeted agent. These conflicting observations raise caution to 
the blanket application of costly sequencing. An alternative is the 
examination of exceptional responders (36). Finding mutational 
events and not being able to determine the role of those molecular 
changes can result in misdirection of therapy and potentially 
harm the patient clinically and economically, and importantly, 
can dash their hope by lack of success.
The explosion in understanding about the molecular basis of 
cancer, especially in women’s cancers, and in new agents, provides 
an important opportunity for patient education. The physician 
can frame the progress in genomics against the background of 
new agent availability. This can lead to a more informed joint 
decision as to whether referral to a screening/treating trial, such 
as MATCH, or for testing is appropriate for the patient at her 
point in her disease.
Heterogeneity provides some insight into the paucity of cures 
with targeted therapies. A great obstacle to application of person-
alized molecular medicine at this time appears to be cancers them-
selves. Solid tumors have some, or many, molecular events, often 
of uncertain importance, making targeted therapy more difficult 
to select. Discerning driver mutations from facilitating mutations 
from passenger mutations with no biologic consequence remains 
empiric. It is often further complicated by secondary mutations 
in many cases. PI3K mutations are a case in point. Almost all 
epithelial solid tumors have some form of PI3K pathway muta-
tion or dysfunction (37, 38). PI3K inhibitors have been uniformly 
disappointing in solid tumors, while being approved for use in 
lymphomas where there are no PI3K mutations, but there is 
strong pathway activation. The next obstacle, a consequence of the 
molecular variability seen in most solid tumors, is intratumoral 
heterogeneity. Sequencing over disparate geographic areas has 
demonstrated intratumor molecular heterogeneity and allowed 
determination of temporal and spatial clonality (39, 40). It has 
demonstrated that divergence can be an early event.
COnCLUSiOn
The promise of personalized molecular medicine has been 
long in being recognized, although clear progress is evident. 
Gynecologic cancers are complex, and focused attention to 
their genomics, biology, and local tumor microenvironment has 
yielded important clues to new therapeutic directions. While few 
clear drivers have been identified, selection parameters, including 
DNA repair dysfunction, are seen with the role of germline BRCA 
mutations and Lynch syndrome biology. The major opportunity 
and challenge ahead is to develop and validate the tools necessary 
to optimize the application of biomarkers and targeted agents to 
rapidly and efficiently improve cancer care delivery to women 
with gynecologic cancers.
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